Can a cholesterol drug keep atrial fibrillation at bay after ablation?

NCT ID NCT07752758

First seen Aug 07, 2026 ยท Last updated Aug 07, 2026

Summary

This trial tests whether ezetimibe, a common cholesterol-lowering medication, can reduce the return of irregular heartbeats in people with persistent atrial fibrillation who undergo catheter ablation. Half of the 120 participants will take ezetimibe daily for six months after the procedure, while the other half receives standard care. The main goal is to see if ezetimibe lowers the chance of atrial arrhythmia recurrence within six months, potentially offering a simple way to improve long-term outcomes after ablation.

What this could mean

Our plain-language read of the trial. This is informational only โ€” not medical advice or a prediction.

Active substance
Ezetimibe, an oral cholesterol-lowering drug, taken as 10 mg once daily for 6 months after catheter ablation.
What this could lead to
If effective, ezetimibe could become a simple, low-cost addition to post-ablation care, potentially reducing the need for repeat procedures and improving long-term heart rhythm control.
What could go wrong
This is a small pilot study, so results may not be conclusive. Ezetimibe is generally well-tolerated but can cause muscle or liver side effects, and its benefit for AF recurrence is unproven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATRIAL FIBRILLATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

More trials for these conditions

Other studies related to the condition(s) this trial covers.